Lineage Cell Therapeutics
LCTX
LCTX
66 hedge funds and large institutions have $98.9M invested in Lineage Cell Therapeutics in 2016 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 10 increasing their positions, 51 reducing their positions, and 5 closing their positions.
New
Increased
Maintained
Reduced
Closed
more funds holding in top 10
Funds holding in top 10: →
more first-time investments, than exits
New positions opened: | Existing positions closed:
less ownership
Funds ownership: →
less funds holding
Funds holding: →
26% less capital invested
Capital invested by funds: $134M → $98.9M (-$35M)
80% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 51
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $874K
Holders
66
Holding in Top 10
1
Calls
–
Puts
$874K
Top Buyers
| 1 | +$229K | |
| 2 | +$91.2K | |
| 3 | +$85.2K | |
| 4 |
Goldman Sachs
New York
|
+$43K |
| 5 |
RJFSA
Raymond James Financial Services Advisors
St. Petersburg,
Florida
|
+$37K |
Top Sellers
| 1 | -$4.41M | |
| 2 | -$788K | |
| 3 | -$552K | |
| 4 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
-$479K |
| 5 |
AG
Artal Group
Luxembourg
|
-$309K |